Foghorn Therapeutics (FHTX) Non Operating Income (2019 - 2026)

Foghorn Therapeutics' Non Operating Income history runs 8 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• In Q1 2026, Non Operating Income fell 58.37% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $9.7 million (down 42.67% YoY), while the FY2025 annual figure was $12.1 million, down 24.63% from the prior year.
• Non Operating Income was $1.7 million for Q1 2026 at Foghorn Therapeutics, down from $2.2 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $4.7 million in Q3 2024 to a low of $890000.0 in Q1 2022.
• Historically, Non Operating Income has averaged $3.0 million across 5 years, with a median of $3.2 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Non Operating Income soared 1275.69% in 2022, then sank 58.37% in 2026.
• A 5-year view of Non Operating Income shows it stood at $3.0 million in 2022, then advanced by 11.27% to $3.3 million in 2023, then jumped by 34.87% to $4.5 million in 2024, then slumped by 50.82% to $2.2 million in 2025, then decreased by 23.31% to $1.7 million in 2026.
• The last three Non Operating Income figures came in at $1.7 million (Q1 2026), $2.2 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.